Corey N. Fishman

Corey N. Fishman (chief executive) discloses dealings in 3 companies, chiefly Iterum Therapeutics plc, Biospecifics Technologies Corp and Momenta Pharmaceuticals Inc. In total, 16 filings cover trades dated from 30 May 2018 to 6 August 2024.

Market trades split into 3 purchases (€63k) and 1 sale (€122k). On balance, insiders were net sellers of €58k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 4 share grants and 4 option exercises.

A typical purchase (the median) is worth €15k.

Most recently, on 12 August 2024, the filings show an option exercise in Iterum Therapeutics plc. The latest purchase dates back some time: it was published 1,069 days ago, on 20 November 2023. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.